Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

ROIV

Roivant Sciences Ltd

Mar 13 • 01:30PM ET

28.29

-0.26 -0.91 %

Healthcare • Biotechnology • United Kingdom • NASD

Peers: VRTX REGN BIIB BMRN ALNY CRSP INCY NBIX IONS EDIT

| Held by: IJH VTI VB XBI VBK VXF MDY IBB SPMD DFAS

Index	-	P/E	-	EPS (ttm)	-1.17	Insider Own	31.76%	Shs Outstand	709.69M	Perf Week	-1.70%
Market Cap	20.25B	Forward P/E	-	EPS next Y	-1.16	Insider Trans	-11.28%	Shs Float	488.39M	Perf Month	5.56%
Enterprise Value	16.53B	PEG	-	EPS next Q	-0.29	Inst Own	67.22%	Short Float	4.80%	Perf Quarter	39.77%
Income	-809.24M	P/S	1521.20	EPS this Y	-360.64%	Inst Trans	1.53%	Short Ratio	3.39	Perf Half Y	96.32%
Sales	13.31M	P/B	4.70	EPS next Y	-4.81%	ROA	-14.69%	Short Interest	23.46M	Perf YTD	30.37%
Book/sh	6.02	P/C	4.47	EPS next 5Y	-	ROE	-17.11%	52W High	30.33 -6.73%	Perf Year	171.50%
Cash/sh	6.33	P/FCF	-	EPS past 3/5Y	42.73% -99.51%	ROIC	-18.53%	52W Low	8.73 224.06%	Perf 3Y	261.30%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-19.30% -	Gross Margin	60.46%	Volatility	3.97% 3.56%	Perf 5Y	184.75%
Dividend TTM	-	EV/Sales	1241.81	EPS Y/Y TTM	-751.06%	Oper. Margin	-9130.53%	ATR (14)	1.11	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	30.66	Sales Y/Y TTM	-86.36%	Profit Margin	-6079.94%	RSI (14)	55.61	Recom	1.33
Dividend Gr. 3/5Y	- -	Current Ratio	30.66	EPS Q/Q	-262.80%	SMA20	-0.29%	Beta	1.21	Target Price	34.20
Payout	-	Debt/Eq	0.03	Sales Q/Q	-77.83%	SMA50	12.36%	Rel Volume	0.31	Prev Close	28.55
Employees	750	LT Debt/Eq	0.02	Earnings	Feb 06 BMO	SMA200	59.31%	Avg Volume	6.93M	Price	28.29
IPO	Dec 08, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	43.41% -60.65%	Trades		Volume	1,371,481	Change	-0.91%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-02-25	Initiated	Citigroup	Buy	$16
Jul-10-25	Resumed	Goldman	Buy	$19
Feb-15-24	Initiated	Wolfe Research	Outperform	$17
Jan-05-24	Initiated	Piper Sandler	Overweight	$20
Dec-12-23	Initiated	Deutsche Bank	Buy	$14
Oct-17-23	Initiated	Guggenheim	Buy	$17
Jun-08-23	Initiated	BofA Securities	Neutral	$10.50
Oct-27-22	Initiated	JP Morgan	Overweight	$7
May-23-22	Initiated	SVB Leerink	Outperform	$6
Apr-29-22	Initiated	Cantor Fitzgerald	Overweight	$15
Dec-15-21	Initiated	Goldman	Buy	$15
Nov-08-21	Initiated	H.C. Wainwright	Buy	$14
Oct-28-21	Initiated	Citigroup	Buy	$11
Oct-26-21	Initiated	Truist	Buy	$15
Oct-26-21	Initiated	Jefferies	Buy	$10
Oct-26-21	Initiated	Cowen	Outperform

Show Previous Ratings

Mar-04-26 04:04PM	Moderna Stock Pops After Inking $950 Million Covid Vaccine Settlement (Investor's Business Daily) +6.00%
02:35PM	Moderna Settles a Covid Vaccine Patent Lawsuit. What It Means for the Stock. (Barrons.com)
09:55AM	MRNA Stock Gains on $2.25B Deal to Settle Patent Dispute With ROIV, ABUS (Zacks)
09:15AM	Stocks to Watch Wednesday: Coinbase, CrowdStrike, Gitlab, Moderna (The Wall Street Journal)
09:01AM	Moderna Pops After Inking $950 Million Covid Vaccine Settlement (Investor's Business Daily)
08:40AM	Loading…
08:40AM	Moderna and Ross Stores Lead Stock Gainers on Wednesday (24/7 Wall St.)
08:14AM	Moderna's $950 Million Settlement Clears Legal Overhang, Stock Soars (Benzinga)
Mar-03-26 04:15PM	Roivant Announces Genevant Sciences' and Arbutus Biopharma's $2.25 Billion Global Settlement With Moderna (GlobeNewswire)
07:00AM	Priovant Announces FDA Acceptance and Priority Review of New Drug Application for Brepocitinib in Dermatomyositis (GlobeNewswire)
Feb-14-26 01:29AM	Citi Raises Roivant Sciences (ROIV) PT to $35 Following Positive Phase 2 Brepocitinib Data (Insider Monkey)
Feb-10-26 06:41AM	TD Cowen Remains Bullish on Roivant Sciences Ltd. (ROIV) - Here's Why (Insider Monkey)
Feb-08-26 08:39AM	Lumentum, Woodward, And Teradyne Are Among the Top 10 Large-Cap Gainers Last Week (Feb. 2-Feb. 6): Are the Others in Your Portfolio? (Benzinga)
Feb-07-26 06:38AM	Roivant Sciences (ROIV) Soars 19.4% as Pipeline Drugs Progress (Insider Monkey)
Feb-06-26 02:05PM	Roivant Stock Soars On Experimental Skin Drug Delivering 100% Response - Why It Matters (Benzinga) +22.14%
02:00PM	Roivant Sciences Ltd (ROIV) Q3 2025 Earnings Call Highlights: Strategic Advances and Financial ... (GuruFocus.com)
01:25PM	Loading…
01:25PM	Tech Bounces As Software Sell-Off Eases, Dow Jones Hits Records: What's Moving Markets Friday? (Benzinga)
10:10AM	Roivant Sciences Q3 Earnings Call Highlights (MarketBeat)
10:03AM	Roivant Sciences Catapults On A 'Dream Scenario' For Its Blockbuster Hopeful (Investor's Business Daily)
08:15AM	Roivant Sciences Ltd. (ROIV) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Roivant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS) and Reports Financial Results for the Third Quarter Ended December 31, 2025 (GlobeNewswire)
07:00AM	Priovant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS) (GlobeNewswire)
Feb-01-26 07:47AM	January jobs data, Alphabet and Amazon earnings, more Warsh fallout: What to watch this week (Yahoo Finance)
Jan-23-26 04:15PM	Roivant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026 (GlobeNewswire)
Jan-20-26 10:31AM	Sun Pharma Eyes Organon In What Could Be India Pharma's Biggest Cross-Border Deal: Report (Benzinga)
Jan-02-26 10:50AM	Leerink Raises Price Target as Roivant (ROIV) Accelerates Drug Development Pipeline (Insider Monkey)
Dec-22-25 08:10AM	Insider Action: Multimillion-dollar sell-offs across major U.S. companies (CNBC TV)
Dec-11-25 07:30AM	Roivant Highlights Continued Pipeline Progress and Outlook for Company's Next Phase of Growth at 2025 Investor Day (GlobeNewswire) +5.43%
Dec-10-25 02:00AM	A Roivant spinout bets on AI-designed drugs for immune conditions (BioPharma Dive)
02:00AM	A former Roivant spinout bets on AI-designed drugs for immune conditions (BioPharma Dive)
Nov-10-25 02:01PM	Roivant Sciences Ltd (ROIV) Q2 2025 Earnings Call Highlights: Strong Financial Position and ... (GuruFocus.com)
08:25AM	Loading…
08:25AM	Roivant Sciences Ltd. (ROIV) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
07:00AM	Roivant Reports Financial Results for the Second Quarter Ended September 30, 2025, and Provides Business Update (GlobeNewswire)
Nov-06-25 09:15AM	Urogen Pharma (URGN) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
Nov-05-25 09:10AM	LENZ Therapeutics, Inc. (LENZ) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
Nov-04-25 07:30AM	Do You Believe in the Growth Prospects of Roivant Sciences Ltd. (ROIV)? (Insider Monkey)
Oct-27-25 04:10PM	Roivant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025 (GlobeNewswire)
Oct-21-25 05:52AM	Wall Street Has a Mixed Opinion on Roivant Sciences Ltd (ROIV) (Insider Monkey)
Oct-04-25 04:54PM	Roivant's Brepocitinib Phase 3 Dermatomyositis Trial Hits Primary and All Key Secondary Endpoints (Insider Monkey)
Sep-29-25 08:01PM	Vivek Ramaswamy's Bitcoin Play Just Got Bigger: This $1.3B Deal Could Signal Corporate Crypto's Next Phase (Benzinga)
Sep-23-25 12:00PM	Are You Looking for a Top Momentum Pick? Why Roivant Sciences Ltd. (ROIV) is a Great Choice (Zacks)
Sep-22-25 10:21AM	Ramaswamy-backed Strive to buy Semler in $1.3 billion deal all stock deal, boosting Bitcoin holdings (Reuters)
Sep-18-25 10:47AM	Roivant Sciences (ROIV) Hits New All-Time High as Drug Candidate Clinical Trial Posts Impressive Results (Insider Monkey)
10:34AM	Montes Archimedes Acquisition (ROIV) Surges 7.8%: Is This an Indication of Further Gains? (Zacks)
Sep-17-25 04:11PM	Roivant Flirts With A Profit-Taking Zone, Stoked By Promise In Autoimmune Disease (Investor's Business Daily) +7.76%
12:49PM	Why Roivant Sciences Stock Is Soaring Today (Motley Fool)
07:00AM	Roivant and Priovant Announce Positive Phase 3 VALOR Study Results for Brepocitinib in 52-Week Placebo-Controlled Trial in Dermatomyositis (DM) (GlobeNewswire)
Sep-14-25 04:00AM	Vivek Ramaswamy Sells $22.7 Million of Roivant Sciences Stock (Barrons.com)
Sep-11-25 04:30PM	Roivant Named on Fortune Media and Great Place To Work's 2025 Best Workplaces in BioPharma List (GlobeNewswire)
11:11AM	Roivant Sciences Ltd. (ROIV) Wins Orphan Drug Status in Japan for Mosliciguat (Insider Monkey)
Sep-03-25 01:01PM	Roivant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients (GlobeNewswire)
Aug-28-25 11:49PM	Roivant Sciences (ROIV) Announces Q1 2025 Business Update (Insider Monkey)
Aug-12-25 06:42PM	Why Roivant Sciences Stock Bounced Back on Tuesday (Motley Fool)
03:02AM	Roivant Sciences Ltd (ROIV) Q1 2025 Earnings Call Highlights: Strong Cash Position and ... (GuruFocus.com)
Aug-11-25 04:58PM	Why Roivant Sciences Stock Was Slipping on Monday (Motley Fool)
08:15AM	Roivant Sciences Ltd. (ROIV) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Roivant Reports Financial Results for the First Quarter Ended June 30, 2025, and Provides Business Update (GlobeNewswire)
Aug-08-25 09:17AM	What To Expect From Roivant Sciences Ltd (ROIV) Q1 2026 Earnings (GuruFocus.com)
Aug-07-25 06:15PM	Kura Oncology (KURA) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
Aug-05-25 08:10AM	Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
Jul-28-25 04:05PM	Roivant to Report Financial Results for the First Quarter Ended June 30, 2025, and Provide Business Update on Monday, August 11, 2025 (GlobeNewswire)
Jul-24-25 11:47PM	Goldman Sachs Resumes Roivant Sciences (ROIV) Coverage with 'Buy' Rating (Insider Monkey)
Jul-11-25 06:20AM	Should Invesco S&P MidCap 400 GARP ETF (GRPM) Be on Your Investing Radar? (Zacks)
Jun-24-25 12:45PM	Roivant Sciences Subsidiary Pulmovant Publishes Positive Phase 1 Data for Inhaled PH Treatment Mosliciguat (Insider Monkey)
Jun-16-25 07:00AM	Pulmovant Announces Publication of Pharmacokinetics and Lung Deposition Data for Inhaled Mosliciguat in Clinical Pharmacokinetics (GlobeNewswire)
Jun-09-25 04:05PM	Roivant and Priovant to Host Investor Video Conference at 1:00 PM ET on Tuesday, June 17 on Brepocitinib and the Unmet Medical Need in Dermatomyositis (GlobeNewswire)
May-29-25 08:15AM	Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Lags Revenue Estimates (Zacks) +6.40%
07:00AM	Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025, and Provides Business Update (GlobeNewswire)
May-28-25 02:17PM	H.C. Wainwright Keeps Buy Rating on Roivant Sciences (ROIV) Stock (Insider Monkey)
09:15AM	What To Expect From Roivant Sciences Ltd (ROIV) Q4 2025 Earnings (GuruFocus.com)
May-15-25 05:15PM	Gossamer Bio (GOSS) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:10PM	Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025 and Provide Business Update on Thursday, May 29, 2025 (GlobeNewswire)
May-14-25 05:40PM	Codexis (CDXS) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
May-13-25 05:10PM	Spero Therapeutics, Inc. (SPRO) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
May-08-25 07:45AM	Liquidia Technologies, Inc. (LQDA) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
May-06-25 06:20AM	Should Invesco S&P MidCap 400 Pure Growth ETF (RFG) Be on Your Investing Radar? (Zacks)
May-02-25 10:37AM	Roivant Sciences Ltd. (ROIV): Among David Einhorn's Stock Picks with Huge Upside Potential (Insider Monkey)
Apr-29-25 11:35AM	Roivant Sciences Ltd. (ROIV): Among Billionaire Andreas Halvorsen's Stock Picks With Huge Upside Potential (Insider Monkey)
Apr-23-25 12:13PM	Roivant Sciences: Primed For Growth With A De-Risked Pipeline (Seeking Alpha)
Apr-21-25 04:08PM	Immunovant Dives On Its C-Suite Sweep, Narrowed Plans For Leading Drug (Investor's Business Daily)
10:18AM	Immunovant Crumbles After Roivant Sweeps Out Its C-Suite, Unveils Strategic Shift (Investor's Business Daily)
07:00AM	Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjogren's Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402 (GlobeNewswire)
07:00AM	Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sj gren's Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402 (GlobeNewswire)
Apr-14-25 06:20AM	Is Invesco S&P MidCap 400 Pure Growth ETF (RFG) a Strong ETF Right Now? (Zacks)
Apr-11-25 03:07PM	Is Roivant Sciences Ltd. (ROIV) the Top Healthcare Stock to Buy According to Billionaire David Einhorn? (Insider Monkey)
10:04AM	Certara (CERT) Soars 8.0%: Is Further Upside Left in the Stock? (Zacks)
Apr-10-25 05:08PM	Roivant Sciences Ltd. (ROIV): Among the Best Low Priced Growth Stocks to Invest In (Insider Monkey)
Mar-31-25 04:03PM	Impax Small Cap Fund Q4 2024 Commentary (Seeking Alpha)
Mar-29-25 04:00PM	Is Roivant Sciences (ROIV) the Best Mid Cap Biotech Stock to Buy? (Insider Monkey)
Mar-25-25 02:12PM	Is Roivant Sciences Ltd. (NASDAQ:ROIV) One of The Best Stocks to Buy According to Billionaire David Einhorn? (InsiderMonkey)
Mar-19-25 04:04PM	Roivant And Immunovant Won't Seek Approval Despite Phase 3 Win. Why Shares Rose. (Investor's Business Daily)
09:26AM	Roivant, Immunovant Succeed In Phase 3. But There's A Twist And Shares Tumbled. (Investor's Business Daily)
07:45AM	Roivant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies (GlobeNewswire)
Mar-18-25 04:32PM	Roivant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs (GlobeNewswire)
Mar-03-25 09:15AM	Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna (GlobeNewswire) -5.31%
Feb-25-25 08:00AM	Early Warning Report Issued Pursuant to National Instrument 62 103: Roivant announces Resignation and Replacement of Arbutus Board (GlobeNewswire)
Feb-12-25 10:00AM	Roivant Sciences price target lowered to $12 from $13 at BofA (TipRanks)
Feb-10-25 07:00AM	Roivant Reports Financial Results for the Third Quarter Ended December 31, 2024, and Provides Business Update (GlobeNewswire)
Feb-07-25 07:06AM	What To Expect From Roivant Sciences Ltd (ROIV) Q3 2025 Earnings (GuruFocus.com)
Feb-03-25 07:00AM	Zest Health Announces $13M in Funding to Curb Unnecessary Pharmaceutical Spend through High-Touch Care (GlobeNewswire)

Roivant Sciences Ltd. engages in the biopharmaceutical business, which engages in the development of transformative medicine. Its product portfolio includes Vtama, Batoclimab, Brepocitinib, Namilumab, and RVT-2001, which aims to treat psoriasis, atopic dermatitis, thyroid eye disease, and other illnesses. The company was founded by Vivek Ramaswamy on April 7, 2014 and is headquartered in London, the United Kingdom.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Torti Frank	President and Vant Chair	Feb 19 '26	Option Exercise	3.85	1,400,000	5,390,000	15,136,547	Feb 23 08:40 PM
Torti Frank	President and Vant Chair	Feb 20 '26	Option Exercise	3.85	1,012,610	3,898,548	14,749,157	Feb 23 08:40 PM
Torti Frank	President and Vant Chair	Feb 23 '26	Option Exercise	3.85	587,390	2,261,452	14,323,937	Feb 23 08:40 PM
Torti Frank	President and Vant Chair	Feb 19 '26	Sale	27.42	1,400,000	38,388,000	13,736,547	Feb 23 08:40 PM
Torti Frank	President and Vant Chair	Feb 20 '26	Sale	27.15	1,012,610	27,492,362	13,736,547	Feb 23 08:40 PM
Torti Frank	President and Vant Chair	Feb 23 '26	Sale	27.51	587,390	16,159,099	13,736,547	Feb 23 08:40 PM
FRANK TORTI	Officer	Feb 20 '26	Proposed Sale	27.52	1,600,000	44,032,000		Feb 20 04:29 PM
FRANK TORTI	Officer	Feb 19 '26	Proposed Sale	27.48	1,400,000	38,472,000		Feb 19 04:24 PM
Venker Eric	President & Immunovant CEO	Feb 13 '26	Option Exercise	3.85	200,000	770,000	1,854,597	Feb 18 05:57 PM
Venker Eric	President & Immunovant CEO	Feb 13 '26	Sale	26.49	200,000	5,298,000	1,654,597	Feb 18 05:57 PM
MANCHESTER KEITH S	Director	Feb 12 '26	Sale	26.75	425,000	11,367,000	15,503,113	Feb 13 09:02 PM
MANCHESTER KEITH S	Director	Feb 11 '26	Sale	26.67	425,000	11,334,750	15,928,113	Feb 13 09:02 PM
MANCHESTER KEITH S	Director	Feb 13 '26	Sale	26.50	375,784	9,956,768	15,127,329	Feb 13 09:02 PM
Gold Daniel Allen	Director	Feb 12 '26	Sale	26.75	425,000	11,367,000	15,503,113	Feb 13 09:00 PM
Gold Daniel Allen	Director	Feb 11 '26	Sale	26.67	425,000	11,334,750	15,928,113	Feb 13 09:00 PM
Gold Daniel Allen	Director	Feb 13 '26	Sale	26.50	375,784	9,956,768	15,127,329	Feb 13 09:00 PM
QVT Financial LP	Director by Deputization	Feb 12 '26	Sale	26.75	425,000	11,367,000	15,503,113	Feb 13 08:45 PM
QVT Financial LP	Director by Deputization	Feb 11 '26	Sale	26.67	425,000	11,334,750	15,928,113	Feb 13 08:45 PM
QVT Financial LP	Director by Deputization	Feb 13 '26	Sale	26.50	375,784	9,956,768	15,127,329	Feb 13 08:45 PM
Venker Eric	Officer	Feb 13 '26	Proposed Sale	26.49	200,000	5,298,373		Feb 13 04:21 PM
Sukhatme Mayukh	President & CIO	Feb 09 '26	Option Exercise	12.68	651,558	8,261,755	19,488,105	Feb 11 05:53 PM
Sukhatme Mayukh	President & CIO	Feb 09 '26	Sale	26.47	339,441	8,985,003	19,148,664	Feb 11 05:53 PM
Sukhatme Mayukh	Officer	Feb 09 '26	Proposed Sale	26.47	339,441	8,985,276		Feb 09 04:13 PM
Venker Eric	President & Immunovant CEO	Jan 12 '26	Option Exercise	3.85	200,000	770,000	1,854,597	Jan 14 09:00 PM
Venker Eric	President & Immunovant CEO	Jan 12 '26	Sale	21.92	200,000	4,384,000	1,654,597	Jan 14 09:00 PM
Venker Eric	Officer	Jan 12 '26	Proposed Sale	21.92	200,000	4,383,694		Jan 12 04:04 PM
Sukhatme Mayukh	President & CIO	Dec 31 '25	Option Exercise	12.68	2,449,877	31,064,440	21,286,424	Dec 31 09:00 PM
Sukhatme Mayukh	President & CIO	Dec 29 '25	Option Exercise	12.68	748,358	9,489,179	19,584,905	Dec 31 09:00 PM
Sukhatme Mayukh	President & CIO	Dec 31 '25	Sale	21.71	1,018,995	22,122,381	20,267,429	Dec 31 09:00 PM
Sukhatme Mayukh	President & CIO	Dec 29 '25	Sale	21.74	311,873	6,780,119	19,273,032	Dec 31 09:00 PM
Sukhatme Mayukh	Officer	Dec 31 '25	Proposed Sale	21.71	1,018,995	22,119,828		Dec 31 04:30 PM
Pulik Richard	CFO	Dec 23 '25	Option Exercise	3.85	260,000	1,001,000	646,144	Dec 29 09:00 PM
Pulik Richard	CFO	Dec 23 '25	Sale	22.43	406,731	9,122,307	239,413	Dec 29 09:00 PM
Venker Eric	President & Immunovant CEO	Dec 23 '25	Option Exercise	3.85	313,841	1,208,288	1,811,749	Dec 29 09:00 PM
Venker Eric	President & Immunovant CEO	Dec 24 '25	Option Exercise	3.85	117,848	453,715	1,729,597	Dec 29 09:00 PM
Venker Eric	President & Immunovant CEO	Dec 23 '25	Sale	22.45	200,000	4,490,000	1,611,749	Dec 29 09:00 PM
Venker Eric	President & Immunovant CEO	Dec 24 '25	Sale	22.53	75,000	1,689,750	1,654,597	Dec 29 09:00 PM
Sukhatme Mayukh	Officer	Dec 29 '25	Proposed Sale	21.74	311,873	6,781,263		Dec 29 04:31 PM
ERIC VENKER	Officer	Dec 24 '25	Proposed Sale	22.53	75,000	1,689,562		Dec 29 09:36 AM
FRANK M TORTI	Officer	Dec 24 '25	Proposed Sale	22.47	64,891	1,458,373		Dec 29 09:05 AM
RICHARD PULIK	Officer	Dec 23 '25	Proposed Sale	22.45	260,000	5,835,726		Dec 23 04:19 PM
RICHARD PULIK TRUST	Officer	Dec 23 '25	Proposed Sale	22.39	146,731	3,285,755		Dec 23 04:07 PM
ERIC VENKER	Officer	Dec 23 '25	Proposed Sale	22.45	200,000	4,490,540		Dec 23 04:04 PM
Sukhatme Mayukh	President & CIO	Dec 17 '25	Option Exercise	12.68	59,513	754,625	18,896,060	Dec 19 09:04 PM
Sukhatme Mayukh	President & CIO	Dec 17 '25	Sale	23.09	26,831	619,528	18,869,229	Dec 19 09:04 PM
Gold Daniel Allen	Director	Dec 16 '25	Sale	23.04	917,282	21,129,619	17,130,445	Dec 18 07:54 PM
Gold Daniel Allen	Director	Dec 17 '25	Sale	23.07	777,332	17,935,595	16,353,113	Dec 18 07:54 PM
MANCHESTER KEITH S	Director	Dec 16 '25	Sale	23.04	917,282	21,129,619	17,130,445	Dec 18 07:52 PM
MANCHESTER KEITH S	Director	Dec 17 '25	Sale	23.07	777,332	17,935,595	16,353,113	Dec 18 07:52 PM
QVT Financial LP	Director by Deputization	Dec 16 '25	Sale	23.04	917,282	21,129,619	17,130,445	Dec 18 07:41 PM
QVT Financial LP	Director by Deputization	Dec 17 '25	Sale	23.07	777,332	17,935,595	16,353,113	Dec 18 07:41 PM
Gline Matthew	CEO	Dec 15 '25	Option Exercise	12.16	3,870,659	47,062,049	19,559,933	Dec 17 09:00 PM
Gline Matthew	CEO	Dec 15 '25	Sale	21.68	1,740,000	37,723,200	17,290,820	Dec 17 09:00 PM
Sukhatme Mayukh	Officer	Dec 17 '25	Proposed Sale	23.09	26,831	619,488		Dec 17 05:09 PM
Ramaswamy Vivek	10% Owner	Dec 12 '25	Option Exercise	12.68	4,672,724	59,250,140	38,326,479	Dec 15 09:34 PM
Ramaswamy Vivek	10% Owner	Dec 11 '25	Option Exercise	12.68	1,869,691	23,707,682	35,523,447	Dec 15 09:34 PM
Ramaswamy Vivek	10% Owner	Dec 15 '25	Option Exercise	12.68	832,453	10,555,504	34,486,208	Dec 15 09:34 PM
Ramaswamy Vivek	10% Owner	Dec 12 '25	Sale	21.96	1,975,858	43,389,842	36,350,621	Dec 15 09:34 PM
Ramaswamy Vivek	10% Owner	Dec 11 '25	Sale	21.64	774,142	16,752,433	34,749,305	Dec 15 09:34 PM
Ramaswamy Vivek	10% Owner	Dec 15 '25	Sale	22.05	353,745	7,800,077	34,132,463	Dec 15 09:34 PM
Gline Matthew	Officer	Dec 15 '25	Proposed Sale	21.68	1,740,000	37,723,200		Dec 15 04:36 PM
Roivant Sciences Ltd.	Director	Dec 12 '25	Buy	21.00	16,666,666	349,999,986	113,317,007	Dec 12 05:17 PM
Venker Eric	President & Immunovant CEO	Dec 09 '25	Option Exercise	3.85	200,000	770,000	1,697,908	Dec 11 09:00 PM
Venker Eric	President & Immunovant CEO	Dec 09 '25	Sale	20.85	200,000	4,170,000	1,497,908	Dec 11 09:00 PM
Venker Eric	Officer	Dec 09 '25	Proposed Sale	20.85	200,000	4,169,131		Dec 09 04:49 PM
MANCHESTER KEITH S	Director	Nov 19 '25	Sale	20.23	1,300,000	26,304,500	18,047,727	Nov 21 08:24 PM
Gold Daniel Allen	Director	Nov 19 '25	Sale	20.23	1,300,000	26,304,500	18,047,727	Nov 21 08:22 PM
QVT Financial LP	Director by Deputization	Nov 19 '25	Sale	20.23	1,300,000	26,304,500	18,047,727	Nov 21 08:15 PM
Ramaswamy Vivek	10% Owner	Nov 14 '25	Sale	20.33	1,027,670	20,892,531	34,193,406	Nov 17 05:52 PM
Ramaswamy Vivek	10% Owner	Nov 17 '25	Sale	20.51	539,650	11,068,222	33,653,756	Nov 17 05:52 PM
Ramaswamy Vivek	10% Owner	Nov 13 '25	Sale	20.81	287,283	5,978,359	35,221,076	Nov 17 05:52 PM
Venker Eric	President & Immunovant CEO	Nov 07 '25	Option Exercise	3.85	200,000	770,000	1,704,959	Nov 07 09:00 PM
Venker Eric	President & Immunovant CEO	Nov 07 '25	Sale	20.22	200,000	4,044,000	1,504,959	Nov 07 09:00 PM
Venker Eric	Officer	Nov 07 '25	Proposed Sale	20.22	200,000	4,043,960		Nov 07 03:15 PM
Venker Eric	President & Immunovant CEO	Oct 15 '25	Option Exercise	15.85	414,683	6,572,726	1,919,642	Oct 17 09:00 PM
Venker Eric	President & Immunovant CEO	Oct 16 '25	Option Exercise	15.85	318,282	5,044,770	1,823,241	Oct 17 09:00 PM
Venker Eric	President & Immunovant CEO	Oct 17 '25	Option Exercise	15.85	118,418	1,876,925	1,623,377	Oct 17 09:00 PM
Venker Eric	President & Immunovant CEO	Oct 15 '25	Sale	16.93	414,683	7,020,583	1,504,959	Oct 17 09:00 PM
Venker Eric	President & Immunovant CEO	Oct 16 '25	Sale	17.05	318,282	5,426,708	1,504,959	Oct 17 09:00 PM
Venker Eric	President & Immunovant CEO	Oct 17 '25	Sale	17.06	118,418	2,020,211	1,504,959	Oct 17 09:00 PM
Venker Eric	Officer	Oct 17 '25	Proposed Sale	17.06	118,418	2,020,171		Oct 17 04:01 PM
Venker Eric	Officer	Oct 16 '25	Proposed Sale	17.05	318,282	5,425,645		Oct 16 04:37 PM
Venker Eric	Officer	Oct 15 '25	Proposed Sale	16.93	414,683	7,021,429		Oct 15 04:23 PM
Venker Eric	President & Immunovant CEO	Oct 09 '25	Option Exercise	15.85	104,940	1,663,299	1,609,899	Oct 14 09:00 PM
Venker Eric	President & Immunovant CEO	Oct 13 '25	Option Exercise	15.85	20,727	328,523	1,525,686	Oct 14 09:00 PM
Venker Eric	President & Immunovant CEO	Oct 09 '25	Sale	16.30	104,940	1,710,522	1,504,959	Oct 14 09:00 PM
Venker Eric	President & Immunovant CEO	Oct 13 '25	Sale	16.25	20,727	336,814	1,504,959	Oct 14 09:00 PM
Venker Eric	Officer	Oct 13 '25	Proposed Sale	16.25	20,727	336,877		Oct 14 08:51 AM
Venker Eric	Officer	Oct 09 '25	Proposed Sale	16.30	104,940	1,710,040		Oct 09 04:12 PM
Venker Eric	President & Immunovant CEO	Oct 07 '25	Option Exercise	7.21	355,161	2,559,093	1,860,120	Oct 08 09:00 PM
Venker Eric	President & Immunovant CEO	Oct 06 '25	Option Exercise	13.29	171,396	2,277,775	1,676,355	Oct 08 09:00 PM
Venker Eric	President & Immunovant CEO	Oct 08 '25	Option Exercise	8.07	138,602	1,119,164	1,643,561	Oct 08 09:00 PM
Venker Eric	President & Immunovant CEO	Oct 07 '25	Sale	16.15	355,161	5,735,850	1,504,959	Oct 08 09:00 PM
Venker Eric	President & Immunovant CEO	Oct 06 '25	Sale	16.34	171,396	2,800,611	1,504,959	Oct 08 09:00 PM
Venker Eric	President & Immunovant CEO	Oct 08 '25	Sale	16.20	138,602	2,245,352	1,504,959	Oct 08 09:00 PM
Venker Eric	Officer	Oct 08 '25	Proposed Sale	16.20	138,602	2,244,797		Oct 08 04:15 PM
Venker Eric	Officer	Oct 07 '25	Proposed Sale	16.15	355,161	5,734,289		Oct 07 04:34 PM
Venker Eric	Officer	Oct 06 '25	Proposed Sale	16.34	171,396	2,800,365		Oct 06 04:46 PM
Venker Eric	President & Immunovant CEO	Sep 19 '25	Option Exercise	3.85	1,000,000	3,850,000	2,653,585	Sep 23 09:00 PM
Venker Eric	President & Immunovant CEO	Sep 22 '25	Option Exercise	3.85	562,374	2,165,140	2,532,141	Sep 23 09:00 PM

MP MP Materials Corporation daily Stock Chart

Peers: REE

| Held by: VTI IJH VB XME REMX VBK VXF MDY SPMD IWR

Index	-	P/E	-	EPS (ttm)	-0.52	Insider Own	19.31%	Shs Outstand	177.36M	Perf Week	-1.51%
Market Cap	10.19B	Forward P/E	51.40	EPS next Y	1.12	Insider Trans	-2.83%	Shs Float	143.36M	Perf Month	-5.33%
Enterprise Value	9.81B	PEG	-	EPS next Q	-0.00	Inst Own	66.74%	Short Float	16.26%	Perf Quarter	-1.17%
Income	-85.87M	P/S	36.99	EPS this Y	223.26%	Inst Trans	0.68%	Short Ratio	3.11	Perf Half Y	-9.01%
Sales	275.46M	P/B	5.14	EPS next Y	277.20%	ROA	-2.66%	Short Interest	23.32M	Perf YTD	13.52%
Book/sh	11.16	P/C	5.56	EPS next 5Y	-	ROE	-4.98%	52W High	100.25 -42.79%	Perf Year	135.23%
Cash/sh	10.31	P/FCF	-	EPS past 3/5Y	- -13.01%	ROIC	-2.56%	52W Low	18.64 207.66%	Perf 3Y	95.20%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-19.47% 15.45%	Gross Margin	-2.80%	Volatility	6.28% 6.17%	Perf 5Y	35.64%
Dividend TTM	-	EV/Sales	35.60	EPS Y/Y TTM	-26.93%	Oper. Margin	-44.48%	ATR (14)	3.93	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	6.67	Sales Y/Y TTM	35.12%	Profit Margin	-31.18%	RSI (14)	44.66	Recom	1.07
Dividend Gr. 3/5Y	- -	Current Ratio	7.24	EPS Q/Q	134.58%	SMA20	-3.08%	Beta	1.60	Target Price	78.62
Payout	-	Debt/Eq	0.43	Sales Q/Q	70.04%	SMA50	-6.33%	Rel Volume	0.67	Prev Close	60.03
Employees	998	LT Debt/Eq	0.40	Earnings	Feb 26 AMC	SMA200	-2.55%	Avg Volume	7.51M	Price	57.35
IPO	Jun 22, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	30100.00% -10.27%	Trades		Volume	3,210,143	Change	-4.47%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-13-26	Initiated	William Blair	Outperform
Dec-05-25	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$71
Nov-24-25	Upgrade	BMO Capital Markets	Market Perform → Outperform	$75
Nov-19-25	Initiated	Goldman	Buy	$77
Nov-14-25	Upgrade	JP Morgan	Neutral → Overweight
Nov-10-25	Upgrade	Deutsche Bank	Hold → Buy	$71
Oct-09-25	Resumed	BMO Capital Markets	Market Perform	$76
Sep-23-25	Initiated	Daiwa Securities	Outperform	$80
Aug-01-25	Upgrade	Jefferies	Hold → Buy	$80
Jul-31-25	Resumed	Morgan Stanley	Equal-Weight	$65
Jul-07-25	Downgrade	Jefferies	Buy → Hold	$33
Jun-05-25	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$34
Sep-27-24	Reiterated	Robert W. Baird	Outperform	$20 → $25
Jul-15-24	Initiated	BMO Capital Markets	Market Perform	$16.50
Apr-23-24	Downgrade	JP Morgan	Overweight → Neutral	$20 → $16
Mar-13-24	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$26 → $15.50
Sep-06-23	Upgrade	Northland Capital	Market Perform → Outperform
Aug-31-23	Initiated	JP Morgan	Overweight	$27
Apr-18-23	Downgrade	Northland Capital	Outperform → Market Perform	$32
Jul-13-22	Initiated	Canaccord Genuity	Buy	$44

Show Previous Ratings

Mar-12-26 05:00AM	Six Stocks That Could Soar in an Era of Regional Instability (Oilprice.com)
Mar-10-26 02:53PM	Another Historic Bull Signal Flashing for Rare Earths Stock (Schaeffer's Research)
02:15PM	USAR Gains 62.7% in the Past Year: Buy, Sell or Hold the Stock? (Zacks)
09:57AM	William Blair Says MP Materials Corp. (MP) Key to US Rare Earth Independence (Insider Monkey)
Mar-09-26 12:24PM	MP Sets Production Records in 2025: Can 2026 go Even Higher? (Zacks)
09:15AM	Loading…
09:15AM	Antimony Emerges as Strategic Growth Play in $4B+ Critical Minerals Market (PR Newswire)
08:15AM	The Defense Stock You've Never Heard Of: Why MP Materials Is a Buy (24/7 Wall St.)
Mar-06-26 02:42PM	Rare Earth Stocks: REalloys Lights Up As Iran War Stokes Demand (Investor's Business Daily)
Mar-05-26 04:05PM	MP Materials to Participate in Upcoming Conferences (Business Wire) -5.08%
Mar-04-26 04:06PM	From Copper To Uranium, YieldMax's MINY Taps Mining Tailwinds (Benzinga)
11:24AM	Rare Earth Stocks: REalloys Takes Off In 2nd Week; MP, USAR Set Up (Investor's Business Daily)
10:09AM	Jim Cramer on MP Materials: "We're Not Going to Let This One Go Away" (Insider Monkey)
Mar-03-26 08:00AM	China's Rare Earth Dominance and the Strategic Failure of the West (PR Newswire)
Mar-02-26 03:49PM	Rare Earth Stocks Flash Buy Signals As Missiles Fly (Investor's Business Daily) +8.26%
12:44PM	JPMorgan Maintains Positive Stance on MP Materials Corp. (MP) Ahead of Q4 (Insider Monkey)
07:13AM	Loading…
07:13AM	MP Materials execs share next steps for $1.3B Texas rare earth magnet site (Manufacturing Dive)
Feb-28-26 12:35PM	MP Materials Q4 Earnings Call Highlights (MarketBeat)
Feb-27-26 06:04PM	Stocks to Watch Friday Recap: Dell, Duolingo, Compass, CoreWeave (The Wall Street Journal) +8.26%
04:23PM	MP Materials Stock Drops After Earnings Beat. Its Added to the Rare-Earths Drama. (Barrons.com)
11:16AM	MP Materials posts Q4 profit, unveils $1.25B Texas magnet factory plans (Proactive)
11:02AM	MP Materials vs. USA Rare Earth: Which Rare-Earth Stock has an Edge? (Zacks)
10:38AM	Stocks to Watch Friday: Nvidia, Dell, Duolingo, Compass (The Wall Street Journal)
10:38AM	Stocks to Watch Friday: Nvidia, Dell, CoreWeave, Duolingo (The Wall Street Journal)
10:38AM	Stocks to Watch Friday: Dell, Duolingo, Compass, CoreWeave (The Wall Street Journal)
05:42AM	MP Materials Stock Rises After Earnings Beat. Its Added to the Rare-Earths Drama. (Barrons.com)
12:01AM	MP Materials Corp (MP) Q4 2025 Earnings Call Highlights: Record REO Production and Strategic ... (GuruFocus.com)
Feb-26-26 06:15PM	Block, Netflix, Paramount, Dell: Stocks to Watch in Afterhours Trading (The Wall Street Journal)
06:11PM	MP Materials Inks Rare Earths Deal With Mystery Automaker (Bloomberg)
06:00PM	MP Materials Corp. (MP) Q4 Earnings Beat Estimates (Zacks)
05:27PM	MP Materials Beat on Earnings, Missed on Sales. The Stock Dips After the Close. (Barrons.com)
04:58PM	Loading…
04:58PM	MP Materials Revenue Falls After Halting Rare Earth Sales to China (The Wall Street Journal)
04:05PM	MP Materials Reports Fourth Quarter and Full Year 2025 Results (Business Wire)
01:00PM	MP Materials Earnings Could Mark a Turning Point for the Rare Earth Producer (Barrons.com)
10:58AM	Five Rare Earth Stocks To Watch As Shortages Hit Aerospace (Investor's Business Daily)
10:19AM	Rare-Earth Miner MP Materials to Invest More Than $1.25 Billion in New Texas Factory (The Wall Street Journal)
09:25AM	MP Materials Selects Northlake, Texas, as the Site of "10X," a New U.S. Rare Earth Magnet Manufacturing Campus (Business Wire)
09:25AM	MP Materials Is Lifting Output of Rare-Earth Magnets. This Is Where. (Barrons.com)
08:00AM	How China Built the World's Largest Manufacturing Machine, With Rare Earths as the Weapon (PR Newswire)
06:00AM	Trumps Secret Weapon in the Rare Earth War (Oilprice.com)
Feb-24-26 02:11PM	These Are the Top 5 Stocks to Own for 2026, According to ChatGPT (Barchart)
10:44AM	Rare Earth Stocks Warm Up As Oxide Prices Climb; REalloys To Start Trading (Investor's Business Daily)
09:06AM	Rare Earth Stock REalloys To Start Trading As Oxide Prices Climb (Investor's Business Daily)
Feb-23-26 12:16PM	What Should be Your Stance on MP Stock Ahead of Q4 Earnings? (Zacks)
10:33AM	Nvidia, Joby, CoreWeave, Lucid and More Stocks with Earnings This Week (Benzinga)
Feb-20-26 10:30AM	Goldman Sachs Says MP Materials Stock Can Gain More Than 30% From Here. Should You Buy MP Stock? (Barchart) -5.50%
Feb-19-26 01:00PM	The Week Ahead: February Closes with Inflation Data, Dow Earnings (Schaeffer's Research)
11:06AM	Northrop's Valuation Is Taking Off. This Is Why. (Barrons.com)
10:00AM	MP Materials Corp. (MP) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
09:36AM	ETFs to Gain as Japan Pledges to Invest $36B in U.S. Projects (Zacks)
Feb-18-26 01:51PM	Trump's $550B Japan Deal Puts LNG, GE Vernova, And Rare Earth Stocks In Focus (Benzinga)
08:15AM	5 Top 2026 Stock Picks Are Companies Backed by Massive US Government Stakes (24/7 Wall St.)
Feb-17-26 03:05PM	Rare Earth Stock Tests Historically Bullish Trendline (Schaeffer's Research)
Feb-16-26 06:00AM	Top U.S. General Joins the Fight for Rare Earth Security (Oilprice.com)
Feb-13-26 01:00PM	MP Materials Backed By $110 DoD Price Floor As JPMorgan Sees 33% Upside (Benzinga)
08:36AM	Are Options Traders Betting on a Big Move in MP Materials Stock? (Zacks)
Feb-12-26 12:50PM	MP Stock Surges 148% in a Year: Worth Including in Your Portfolio? (Zacks) -5.41%
06:42AM	Trump's Favorite Commodity Is Coming To Derivatives Market (Benzinga)
Feb-09-26 03:57PM	Insiders Buy 3 High-Risk StocksHeres Whats Driving the Moves (MarketBeat)
Feb-05-26 12:18PM	A $3 Billion Reason to Buy This Rare Earths Stock (Barchart) -6.61%
08:40AM	U.S. Minerals Stocks Tumble After White House Signals Market Controls (GuruFocus.com)
Feb-04-26 04:41PM	These Stocks Are Todays Movers: AMD, AbbVie, Boston Scientific, Eli Lilly, MP Materials, Super Micro, Palantir, and More (Barrons.com) -6.28%
04:23PM	MP Stock Tanked as Vance, Rubio Talked Critical Minerals (Barrons.com)
11:33AM	MP Stock Is Tanking as Vance, Rubio Talk Critical Minerals (Barrons.com)
07:00AM	North American Company Secures Strategic Rare Earth Deal in Kazakhstan (Oilprice.com)
Feb-03-26 12:04PM	Project Vault 'Puts America's Best Foot Forward'-Rare Earth Stocks Dig It (Benzinga) +9.30%
06:27AM	Critical Metals, USA Rare Earth, MP Materials Climb In Tuesday Pre-Market: What's Going On? (Benzinga)
Feb-02-26 05:02PM	Where the Smart Money Is Focused in Defense (Barrons.com)
04:24PM	Trump Wants a Critical Minerals Stockpile. What It Means for MP Stock. (Barrons.com)
04:14PM	These Stocks Are Todays Movers: Strategy, Robinhood, Oracle, Palantir, Nvidia, Disney, MP Materials, and More (Barrons.com)
01:51PM	MP Materials Stock Rises As Trump Unveils Strategic Vault Initiative (Benzinga)
01:24PM	Trump launches $12 bln minerals stockpile to counter China (Reuters Videos)
12:39PM	US $12 Billion Critical Minerals Stockpile Puts Rare Earth ETFs Back In Focus (Benzinga)
12:17PM	3 Stocks Trump Could Back Next as USA Rare Earths Revives the Federal Catalyst Trade (MarketBeat)
12:03PM	Rare Earth Stocks Rise On Trump $12 Billion Stockpile Report (Investor's Business Daily)
11:19AM	Stocks Gain on US Manufacturing Strength (Barchart)
10:14AM	Stock Indexes Climb as Chip Makers and AI Infrastructure Stocks Rebound (Barchart)
09:51AM	Trump Wants a Critical Minerals Stockpile, Report Says. What It Means for MP Stock. (Barrons.com)
09:34AM	Trump administration to create a strategic reserve for rare earth elements (Associated Press Finance)
09:18AM	Trump Wants a Critical Minerals Stockpile, Report Says. What It Means for MP, Peer Stocks. (Barrons.com)
08:39AM	Trump Reportedly Set To Launch $12 Billion Critical Mineral Stockpile To Counter China: AAPL, GM, GOOG, BA In Focus (Benzinga)
Jan-31-26 04:25PM	Can MP Materials Stock Beat the Market in 2026? (Motley Fool)
10:08AM	Who Wins When Washington Plays Favorites? (Bloomberg)
Jan-30-26 12:31PM	Trump Administration Changes Stance On Critical Minerals Price Floors: Report (Benzinga) -5.45%
09:37AM	Why Shares in MP Materials Slumped This Week (Motley Fool)
Jan-29-26 04:59PM	Rare Earth Stocks Tumble On Trump Price Floor Shift (Investor's Business Daily) -7.24%
04:05PM	MP Materials Announces Date for Fourth Quarter 2025 Financial Results and Webcast (Business Wire)
02:54PM	MP Material Stock Sinks on Trump Rare Earth Price-Floor Comment. What to Do Now. (Barrons.com)
02:09PM	MP Materials Stock Is Falling Today: What's Going On? (Benzinga)
01:50PM	Why MP Materials Stock Just Crashed (Motley Fool)
12:59PM	USAR and MP Reprice After Policy Signal Shifts (GuruFocus.com)
12:50PM	United States Antimony Stock Plunges Thursday: What's Happening? (Benzinga)
12:22PM	Why USA Rare Earth Stock Keeps Going Down (Motley Fool)
11:52AM	MP, Rare Earth Stocks Sink on Price-Floor Fears. This Could Be a Buying Opportunity. (Barrons.com)
11:41AM	Rare Earth Stocks Get Rocked: Here Are The Facts (Benzinga)
10:05AM	3 Rare Earth Stocks to Watch in 2026 (Motley Fool)
05:33AM	IBM bounces after earnings, and more early market movers (MarketWatch)
05:31AM	Trump Administration Changes Stance On Critical Minerals Price Floors: Report (Benzinga)
Jan-28-26 09:16PM	Rare Earth Stocks Tumble Late On Trump Price Floor Shift (Investor's Business Daily)
05:44PM	Exclusive-US moves away from critical mineral price floors, sources say (Reuters)
10:45AM	MP vs. LYSDY: Which Rare-Earth Stock Boasts More Upside? (Zacks)

MP Materials Corp. engages in the production and marketing of rare earth specialty materials. It operates through the Materials and Magnetics segments. The Materials segment focuses on the operation of Mountain Pass, which produces refined rare earth oxides and related products, as well as rare earth concentrate products. The Magnetics segment is involved in the operation of Independence Facility, where the company began production of magnetic precursor products. The company was founded by James Henry Litinsky and Michael Rosenthal in 2017 and is headquartered in Las Vegas, NV.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hoops Elliot Dean	General Counsel and Secretary	Jan 20 '26	Sale	68.21	7,823	533,607	74,967	Jan 22 07:48 PM
Elliot Hoops	officer	Jan 20 '26	Proposed Sale	68.21	7,823	533,569		Jan 20 04:36 PM
Litinsky James H.	Chairman and CEO	Jan 08 '26	Sale	64.17	272,600	17,492,742	12,805,965	Jan 09 09:48 PM
Litinsky James H.	Chairman and CEO	Jan 07 '26	Sale	64.01	27,400	1,753,874	13,078,565	Jan 09 09:48 PM
JAMES HENRY LITINSKY REVOCABLE	Director	Jan 08 '26	Proposed Sale	62.50	272,600	17,037,500		Jan 08 04:25 PM
JAMES HENRY LITINSKY REVOCABLE	Director	Jan 07 '26	Proposed Sale	59.82	27,400	1,639,068		Jan 07 04:57 PM
Corbett Ryan	Chief Financial Officer	Dec 09 '25	Sale	60.00	38,146	2,288,760	156,666	Dec 10 09:11 PM
Corbett Ryan	Officer	Dec 09 '25	Proposed Sale	60.00	38,146	2,288,760		Dec 09 04:14 PM
Litinsky James H.	Chairman and CEO	Dec 05 '25	Sale	62.94	385,000	24,232,308	13,105,965	Dec 05 09:45 PM
JAMES HENRY LITINSKY REVOCABLE	Officer	Dec 05 '25	Proposed Sale	62.94	385,000	24,231,092		Dec 05 04:29 PM
Litinsky James H.	Chairman and CEO	Nov 20 '25	Sale	63.86	248,411	15,864,583	13,369,665	Nov 20 09:40 PM
JAMES HENRY LITINSKY REVOCABLE	Officer	Nov 20 '25	Proposed Sale	63.86	248,411	15,864,147		Nov 20 04:23 PM
Corbett Ryan	Chief Financial Officer	Nov 17 '25	Sale	57.72	20,000	1,154,400	194,812	Nov 19 09:21 PM
Corbett Ryan	Officer	Nov 17 '25	Proposed Sale	57.72	20,000	1,154,480		Nov 17 01:13 PM
Rosenthal Michael Stuart	Chief Operating Officer	Aug 29 '25	Sale	72.02	150,000	10,802,838	1,284,409	Aug 29 09:23 PM
Rosenthal Michael Stuart	Officer	Aug 29 '25	Proposed Sale	72.02	150,000	10,803,255		Aug 29 04:20 PM
Hoops Elliot Dean	General Counsel and Secretary	Aug 01 '25	Sale	60.33	6,337	382,304	0	Aug 01 09:22 PM
Hoops Elliot Dean	Officer	Aug 01 '25	Proposed Sale	60.29	6,337	382,038		Aug 01 03:58 PM
Hoops Elliot Dean	General Counsel and Secretary	Jul 01 '25	Sale	31.94	6,338	202,464	6,337	Jul 03 09:27 PM
Hoops Elliot Dean	Officer	Jul 01 '25	Proposed Sale	31.90	6,338	202,209		Jul 01 04:36 PM
Hoops Elliot Dean	General Counsel and Secretary	Jun 26 '25	Sale	36.37	5,523	200,872	69,749	Jun 27 09:30 PM
Hoops Elliot Dean	Officer	Jun 26 '25	Proposed Sale	36.33	5,523	200,651		Jun 26 04:17 PM
Hoops Elliot Dean	General Counsel and Secretary	Jun 13 '25	Sale	29.96	5,538	165,918	12,675	Jun 13 09:25 PM
Hoops Elliot Dean	General Counsel and Secretary	Jun 12 '25	Sale	29.95	800	23,960	18,213	Jun 13 09:25 PM
Hoops Elliot Dean	Officer	Jun 13 '25	Proposed Sale	29.96	6,338	189,900		Jun 13 04:30 PM
Litinsky James H.	Chairman and CEO	Apr 14 '25	Sale	27.08	199,180	5,393,794	13,643,076	Apr 16 09:11 PM
Litinsky James H.	Chairman and CEO	Mar 25 '25	Sale	27.03	396,293	10,711,800	13,860,775	Mar 27 09:40 PM
Litinsky James H.	Chairman and CEO	Mar 26 '25	Sale	27.00	18,519	500,013	13,842,256	Mar 27 09:40 PM
Litinsky James H.	Chairman and CEO	Mar 20 '25	Sale	27.04	95,621	2,585,592	14,257,068	Mar 21 09:15 PM
Litinsky James H.	Chairman and CEO	Mar 18 '25	Sale	26.71	639,294	17,075,543	14,513,864	Mar 19 09:18 PM
Litinsky James H.	Chairman and CEO	Mar 17 '25	Sale	26.77	489,918	13,115,105	15,153,158	Mar 19 09:18 PM
Litinsky James H.	Chairman and CEO	Mar 19 '25	Sale	26.94	161,175	4,342,054	14,352,689	Mar 19 09:18 PM
JAMES HENRY LITINSKY REVOCABLE	Director	Mar 19 '25	Proposed Sale	26.83	788,356	21,151,591		Mar 19 05:04 PM
Corbett Ryan	Chief Financial Officer	Mar 14 '25	Sale	25.51	60,000	1,530,391	230,100	Mar 18 06:45 PM
Corbett Ryan	Chief Financial Officer	Mar 17 '25	Sale	27.00	15,000	405,000	214,812	Mar 18 06:45 PM
JAMES HENRY LITINSKY REVOCABLE	Director	Mar 18 '25	Proposed Sale	26.69	721,726	19,262,867		Mar 18 05:06 PM
JAMES HENRY LITINSKY REVOCABLE	Director	Mar 17 '25	Proposed Sale	26.83	489,918	13,144,500		Mar 17 05:05 PM
Corbett Ryan	Officer	Mar 17 '25	Proposed Sale	27.00	15,000	405,000		Mar 17 04:03 PM
Corbett Ryan	Officer	Mar 14 '25	Proposed Sale	25.00	60,000	1,500,000		Mar 14 04:09 PM

ROIV

Roivant Sciences Ltd

MP

MP Materials Corporation

Upgrade your FINVIZ experience